Search Results for: Potenziale terapia per il cancro del colon metastatico

Efficace nel 30% dei pazienti che non risponde alle altre cure

In Reply On behalf of my coauthors, I appreciate the thoughtful response to our article on the disparities in clinical trial access for patients with advanced-stage cancer. The Letter raises important points that we would like to address. Our study identified the presence of a registered clinical trial open for enrollment at specific zip codes to determine access. As noted, the database may not have captured all clinical trials, particularly those unregistered, even though sponsors and investigators in the US are mandated to submit information to ClinicalTrials.gov. It is possible that some US trials were not listed, which could have affected the comprehensiveness of our findings. Additionally, we acknowledge that age disparities between trial participants and the diagnosed disease population exist, especially in breast, prostate, colon, and lung cancer trials, as described by Zhao et al, with such disparities increasing over time. This is a critical area for further investigation.

ERBB2-pathway activation, through amplification or activating mutations, represents a new target for colon cancer (CC) treatment. We compared molecular methods to the gold-standard for assessing ERBB2 status and determined the prognostic value of ERBB2 amplification, mutations, and expression using data from two phase III trials involving nearly 3,000 stage III CC patients.

Focus su tumori ereditari e immunità nei contesti oncologici

Da Torino l’annuncio di un passo avanti nella lotta al cancro

Via a studio con Italia.Biopsia liquida per nuovo approccio cura

Al via uno studio con l’Italia. La biopsia liquida per un nuovo approccio di cura

La Presidenza del Consiglio aderisce a ‘Illumina novembre’